Cancer Immunology Research

Article	Citations
Abstract P039: The immune profile of colorectal and pancreas adenocarcinomas: Differences between central and peripheric tumor regions	191
Abstract P003: Efficacy results of a novel vaccine composed of stimulated and haptenized tumors cells in Balbc mice grafted with murine colon adenocarcinoma CT26 cells	125
A Sampling of Highlights from the Literature	121
Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy	112
Exercise as an Immune Boost: Mechanism-Driven Support for Lifestyle Interventions	103
Optimal Neoantigen Cancer Vaccines Target CD8+ and CD4+ T Cells with Multiple Antigens	97
Transforming the Dark into Light: A Siglec-9 Switch	91
IL18 at the Crossroads between Chronic Inflammation and T-cell Exhaustion in Pancreatic Cancer	83
CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity	79
Host Interactions with Engineered T-cell Micropharmacies	75
IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma	66
Combination Therapy Approaches to Enhance the Efficacy of ERV-Targeting Vaccines in Cancer	65
Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy	62
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer	61
T-cell Senescence in the Tumor Microenvironment	61
Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies	59
A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types	58
Reciprocal Interactions Between the Gut Microbiome and Mammary Tissue Mast Cells Promote Metastatic Dissemination of HR+ Breast Tumors	57
The ω-3 Polyunsaturated Fatty Acid Docosahexaenoic Acid Enhances NK-Cell Antitumor Effector Functions	56
Single-Cell Analysis of Posttranslational Modifications Identifies Immunosuppressive Macrophage Subtypes in the HBV-Positive Hepatocellular Carcinoma Microenvironment	56
Abstract P073: Gut microbiota shift in melanoma patients undergoing immunotherapy is associated with clinical response	53
Profiling Multiple CD8+ T-cell Functional Dimensions Enhances Breast Cancer Immune Assessment	53
Abstract P009: Correlation between immune modulation of macrophage recruitment and new blood vessel formation in a subcutaneous murine mouse model of colorectal cancer	52
A Sampling of Highlights from the Literature	51
Abstract IA17: The power of ONE: Immunology in the age of single cell genomics	51

High Mobility Group Protein B1 Decreases Surface Localization of PD-1 to Augment T-cell Activation	50
Ncoa2 Promotes CD8+ T cell–Mediated Antitumor Immunity by Stimulating T-cell Activation via Upregulation of PGC-1α Critical for Mitochondrial Function	49
Harnessing Microbiota to Improve Immunotherapy for Gastrointestinal Cancers	47
A Sampling of Highlights from the Literature	47
Engineering CD20 CARs with a Twist	45
Identification and Phenotypic Characterization of Neoantigen-Specific Cytotoxic CD4+ T Cells in Endometrial Cancer	42
Sensory Nerves Impede the Formation of Tertiary Lymphoid Structures and Development of Protective Antimelanoma Immune Responses	41
Ethnicity, Immunity, and Outcomes: Biology versus Socioeconomic Status	41
Low TCR Binding Strength Results in Increased Progenitor-like CD8+ Tumor-Infiltrating Lymphocytes	41
Loss of LRRC33-Dependent TGFβ1 Activation Enhances Antitumor Immunity and Checkpoint Blockade Therapy	41
The HSP90 Inhibitor Pimitespib Targets Regulatory T Cells in the Tumor Microenvironment	40
High Expression of MHC Class I Overcomes Cancer Immunotherapy Resistance Due to IFNγ Signaling Pathway Defects	40
Cannabidiol Enhances Atezolizumab Efficacy by Upregulating PD-L1 Expression via the cGAS–STING Pathway in Triple-Negative Breast Cancer Cells	39
Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity	37
The SETDB1–TRIM28 Complex Suppresses Antitumor Immunity	37
KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer	37
Neoadjuvant STING Activation, Extended Half-life IL2, and Checkpoint Blockade Promote Metastasis Clearance via Sustained NK-cell Activation	36
Fueling T-cell Antitumor Immunity: Amino Acid Metabolism Revisited	36
The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission	36
A Sampling of Highlights from the Literature	36
Abstract P027: Extending intratumoral therapeutic durability using a multivalent immunotherapy platform	35
Abstract P011: B cell subsets that correlate with anti-PD-1 resistance in a preclinical model of HPV+ oropharyngeal cancer	34
Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses	33
Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma	33
Navigating Critical Challenges Associated with Immunopeptidomics-Based Detection of Proteasomal Spliced Peptide Candidates	32
Denosumab Enhances Antitumor Immunity by Suppressing SPP1 and Boosting Cytotoxic T Cells	32
Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry	32
Spatial Organization of Macrophages in CTL-Rich Hepatocellular Carcinoma Influences CTL Antitumor Activity	32
About the Rising Star	32
Circulating and Intratumoral Immune Determinants of Response to Atezolizumab plus Bevacizumab in Patients with Variant Histology or Sarcomatoid Renal Cell Carcinoma	31
TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma	30
CCRL2 Expression by Specialized Lung Capillary Endothelial Cells Controls NK-cell Homing in Lung Cancer	30
PRDX-1 Supports the Survival and Antitumor Activity of Primary and CAR-Modified NK Cells under Oxidative Stress	30
PIKfyve Inhibition Induces Antitumor Immunogenicity by Attenuating STING Trafficking and Lysosomal Degradation	28
In vivo labelling resolves distinct temporal, spatial, and functional properties of tumour macrophages, and identifies subset-specific effects of PD-L1 blockade	28
TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer	28
Abstract IA07: Impact of immunotherapy on COVID-19 immunity: Insights from checkpoint blockade in cancer	28
CXCL10 Recruitment of γδ T Cells into the Hypoxic Bone Marrow Environment Leads to IL17 Expression and Multiple Myeloma Progression	27
Abstract P054: Immune determinants of the association between tumor mutational burden and immunotherapy response across cancer types	27
A Sampling of Highlights from the Literature	27
Abstract IA12: Cancer evolution: Chromosomal instability and immune evasion	27
A Sampling of Highlights from the Literature	27
Atypical B Cells Promote Cancer Progression and Poor Response to Bacillus Calmette-Guérin in Non–Muscle Invasive Bladder Cancer	26
Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies	26
Coexisting Alterations of MHC Class I Antigen Presentation and IFNγ Signaling Mediate Acquired Resistance of Melanoma to Post–PD-1 Immunotherapy	26
Determinants for Antitumor and Protumor Effects of Programmed Cell Death	25
Increased CaMKK2 Expression Is an Adaptive Response That Maintains the Fitness of Tumor-Infiltrating Natural Killer Cells	25
Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade	25
The E3 Ubiquitin Ligase FBXO38 Maintains the Antitumor Function of Natural Killer Cells by Sustaining IL15R Signaling	25
IGM-7354, an Immunocytokine with IL15 Fused to an Anti–PD-L1 IgM, Induces NK and CD8+ T cell–Mediated Cytotoxicity of PD-L1–Positive Tumor Cells	24

NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy	24
Intratumoral TREX1 Induction Promotes Immune Evasion by Limiting Type I IFN	24
CAR T-cell Entry into Tumor Islets Is a Two-Step Process Dependent on IFNγ and ICAM-1	24
A Sampling of Highlights from the Literature	24
Battle Within the Sexes: Differences in Male and Female Immunity and the Impact on Antitumor Responses	24
Translating Science into Survival: Report on the Seventh International Cancer Immunotherapy Conference	24
A Sampling of Highlights from the Literature	23
Regulatory Considerations for Genome-Edited T-cell Therapies	23
Adenosine-Deaminase-Acting-on-RNA-1 Facilitates T-cell Migration toward Human Melanoma Cells	22
CD8+ T Cells Keep Their (K+)urrency for Function	22
Antitumor Immune Responses in B2M-Deficient Cancers	22
CAR Binders Affect CAR T-cell Tonic Signaling, Durability, and Sensitivity to Target	22
Cancer Immunology Research: A Decade of Illumination and Innovation	22
A Metabolic Axis of Immune Intractability	22
MerTK Induces Dysfunctional Dendritic Cells by Metabolic Reprogramming	22
Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells	22
About the Rising Star	21
A Sampling of Highlights from the Literature	21
Combination CXCR4 and PD-1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma	21
Abstract P057: Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas	21
Q&A: Lisa H. Butterfield, Elizabeth M. Jaffee, and Arlene H. Sharpe on the SITC–AACR Joint Workshop, “The Cancer Biology Underlying Immunotherapy-Induced Autoimmunity”	21
Abstract IA20: What does not kill it makes it stronger: Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy	21
Plexin-A4 Mediates Cytotoxic T-cell Trafficking and Exclusion in Cancer	21
Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti–PD-1/PD-L1 Agents	20
The PO4-tential for Less Toxic CAR T-cell Therapies	20
The Pellino1–PKCθ Signaling Axis Is an Essential Target for Improving Antitumor CD8+ T-lymphocyte Function	20
M9657 Is a Bispecific Tumor-Targeted Anti-CD137 Agonist That Induces MSLN-Dependent Antitumor Immunity without Liver Inflammation	20
Abstract P075: NTX-1088, a potent first-in-class, anti-PVR mAb, restores expression and function of DNAM1 for optimal DNAM1-mediated antitumor immunity	20
Identification of Core Techniques That Enhance Genome Editing of Human T Cells Expressing Synthetic Antigen Receptors	20
Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy	19
Immunogenetic Metabolomics Reveals Key Enzymes That Modulate CAR T-cell Metabolism and Function	19
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors	19
HER2Δ16 Engages ENPP1 to Promote an Immune-Cold Microenvironment in Breast Cancer	19
A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors	19
TLR5 Signaling Causes Dendritic Cell Dysfunction and Orchestrates Failure of Immune Checkpoint Therapy against Ovarian Cancer	19
The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I–Associated Peptides	18
Nanobody-Directed CEA-Targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts	18
Abstract IA06: Chimeric antigen receptor macrophages for the treatment of solid tumors	18
The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Effi	18
A Sampling of Highlights from the Literature	18
Glioblastoma Cell–Derived lncRNA-Containing Exosomes Induce Microglia to Produce Complement C5, Promoting Chemotherapy Resistance	18
Immune Modulation of Innate and Adaptive Responses Restores Immune Surveillance and Establishes Antitumor Immunologic Memory	17
Long-Read Sequencing Reveals Alternative Splicing-Driven, Shared Immunogenic Neoepitopes Regardless of SF3B1 Status in Uveal Melanoma	17
Abstract P070: The safety and efficacy of Durvalumab and Paclitaxel combination in metastatic triple-negative breast cancer: An open-label phase I/II trial with 2-years follow-up	17
Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models	17
Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple Myeloma	17
CD49a Targeting Enhances NK Cell Function and Antitumor Immunity	17
Small Gene Networks Delineate Immune Cell States and Characterize Immunotherapy Response in Melanoma	17
Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer	16
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer	16
Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function	16
CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer	16
Accounting for B-cell Behavior and Sampling Bias Predicts Anti–PD-L1 Response in Bladder Cancer	16
Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells	16
Low Serum Apolipoprotein A1 Levels Impair Antitumor Immunity of CD8+ T Cells via the HIF-1α–Glycolysis Pathway	16
Combination of Anti–PD-1 and Electroacupuncture Induces a Potent Antitumor Immune Response in Microsatellite-Stable Colorectal Cancer	16
Antigen Priming Induces Functional Reprogramming in iNKT Cells via Metabolic and Epigenetic Regulation: An Insight into iNKT Cell-Based Antitumor Immunotherapy	16
CD4+ Regulatory T Cells in Human Cancer: Subsets, Origin, and Molecular Regulation	16
The Conventional Dendritic Cell 1 Subset Primes CD8+ T Cells and Traffics Tumor Antigen to Drive Antitumor Immunity in the Brain	16
PI3K/Akt signaling pathway regulates CD155 expression involved in resistance to cancer immunotherapy	16
Abstract IA16: Immune suppression in cancer and strategies for its reversal	15
The Dark Knight: Functional Reprogramming of Neutrophils in the Pathogenesis of Colitis-Associated Cancer	15
Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer	15
About the Rising Star	15
Efficacy and Synergy with Cisplatin of an Adenovirus Vectored Therapeutic E1E2E6E7 Vaccine against HPV Genome–Positive C3 Cancers in Mice	15
Abstract P062: PI3Kγδ inhibitor plus radiation enhances the antitumor immune effect of PD-1 blockade in syngenic murine breast cancer and humanized patient-derived xenograft model	15
Let the Guard Down: cAMP Activators Can Improve Immunotherapy in GBM	15
Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer	15
A Sampling of Highlights from the Literature	14
TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids	14
Something Old and Something New to Unleash the Power of Natural Killer Cells against Metastases	14
IDO Vaccine Ablates Immune-Suppressive Myeloid Populations and Enhances Antitumor Effects Independent of Tumor Cell IDO Status	14
The Problem with Syngeneic Mouse Tumor Models	14
iBRIDGE: A Data Integration Method to Identify Inflamed Tumors from Single-cell RNA-Seq Data and Differentiate Cell Type–Specific Markers of Immune-Cell Infiltration	14
A Sampling of Highlights from the Literature	14
The TRIB2–DNMT1 Pathway Generates an Immune-Cold Microenvironment in Glioblastoma, and Its Inhibition Promotes Immunotherapy	14
Tyrosine Kinase Inhibition Activates Intratumoral γδ T Cells in Gastrointestinal Stromal Tumor	14
Interactions between MDSCs and the Autonomic Nervous System: Opportunities and Challenges in Cancer Neuroscience	13
Arginase 1–Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti–PD-1 Checkpoint Blockade	13
FOXO1 Inhibition Generates Potent Nonactivated CAR T Cells against Solid Tumors	13

Tsyn-Seq: a T-cell Synapse–Based Antigen Identification Platform	13
Abstract P068: Automated cell type specific PD-L1 quantification by artificial intelligence using high throughput bleach & stain 15-marker multiplex fluorescence immunohistochemistry in human canc	13
High-Dimensional Analyses Reveal IL15 Enhances Activation of Sipuleucel-T Lymphocyte Subsets and Reverses Immunoresistance	13
Host Tissue Factors Predict Immune Surveillance and Therapeutic Outcomes in Gastric Cancer	13
Abstract P076: Humanized anti-αvβ3 antibody engineered to selectively promote macrophage-mediated cancer cell death	13
The FcγRIIIA (CD16) L48-H/R Polymorphism Enhances NK Cell–Mediated Antibody-Dependent Cellular Cytotoxicity by Promoting Serial Killing	13
Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome	13
Gastric Microbiome Alterations Are Associated with Decreased CD8+ Tissue-Resident Memory T Cells in the Tumor Microenvironment of Gastric Cancer	13
Abstract P051: Function of shp-1 and shp-2 phosphatases in T cell-mediated anti-tumor response	13
Effective Treatment of Established Bone Metastases Can Be Achieved by Combinatorial Osteoclast Blockade and Depletion of Granulocytic Subsets	13
Regulatory Programs of B-cell Activation and Germinal Center Reaction Allow B-ALL Escape from CD19 CAR T-cell Therapy	13
CAR T Cells Engineered to Secrete IFNκ Induce Tumor Ferroptosis via an IFNAR/STAT1/ACSL4 Axis	12
Abstract P041: Simultaneous checkpoint inhibition and immune cell activation that is safely localized to solid tumors	12
Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia	12
CDK2 Inhibition Enhances Antitumor Immunity by Increasing IFN Response to Endogenous Retroviruses	12
Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy	12
Clonal Spreading of Tumor-Infiltrating T Cells Underlies the Robust Antitumor Immune Responses	12
The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy	12
Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy	12
Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors	12
Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity	12
Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients	12
A Sampling of Highlights from the Literature	12
C3aR Signaling Inhibits NK-cell Infiltration into the Tumor Microenvironment in Mouse Models	12
Breast Cancer Stem Cell–Derived Tumors Escape from γδ T-cell Immunosurveillance In Vivo by Modulating γδ T-cell Ligands	12
Tumor Cell–Intrinsic c-Myb Upregulation Stimulates Antitumor Immunity in a Murine Colorectal Cancer Model	12
Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054	11
Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant	11
Engineered CAR-NK Cells with Tolerance to H2O2 and Hypoxia Can Suppress Postoperative Relapse of Triple-Negative Breast Cancers	11
Tumor Necrosis Factor-α–Induced Protein 8-Like 2 Fosters Tumor-Associated Microbiota to Promote the Development of Colorectal Cancer	11
TIGIT affects CAR NK cell effector function in the solid tumor microenvironment by modulating immune synapse strength	11
Supporting the Next Generation of Scientists to Lead Cancer Immunology Research	10
Abstract IA09: Mapping myeloid programs that control tumor immunity	10
A New Year, A New Initiative	10
Close Spatial Interactions between Cancer Cells and Cancer-Associated Fibroblasts Suppress Antitumor Immunity	10
Inhibition of eEF-2K enhances the antitumor efficacy of NK cells	10
Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition	10
Abstract P012: Investigation of interleukin-34 dependent regulation of renal carcinoma tumor microenvironment	10
Enhancing CAR T-cell Therapy Using Fab-Based Constitutively Heterodimeric Cytokine Receptors	10
T cell–Mediated Development of Stromal Fibroblasts with an Immune-Enhancing Chemokine Profile	10
Chronic Stress Exacerbates the Immunosuppressive Microenvironment and Progression of Gliomas by Reducing Secretion of CCL3	10
The Exonuclease TREX1 Constitutes an Innate Immune Checkpoint Limiting cGAS/STING-Mediated Antitumor Immunity	10
A Sampling of Highlights from the Literature	10
About the Rising Star	10
Blocking WNT7A Enhances MHC-I Antigen Presentation and Enhances the Effectiveness of Immune Checkpoint Blockade Therapy	10
mWTX-330, an IL-12 INDUKINE Molecule, Activates and Reshapes Tumor-Infiltrating CD8+ T and NK Cells to Generate Antitumor Immunity	10
Lessons for the Next Generation of Scientists from the Second Annual Arthur and Sandra Irving Cancer Immunology Symposium	9
Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy	9
HRS Regulates Small Extracellular Vesicle PD-L1 Secretion and Is Associated with Anti–PD-1 Treatment Efficacy	9
Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers	9
Abstract P053: Ablation of CCR1 relieves immunosuppression in pancreatic cancer	9
In Situ Detection of Individual Classic MHC-I Gene Products in Cancer	9
Spatial Organization and Prognostic Significance of NK and NKT-like Cells via Multimarker Analysis of the Colorectal Cancer Microenvironment	9
Targeting the IL1β Pathway for Cancer Immunotherapy Remodels the Tumor Microenvironment and Enhances Antitumor Immune Responses	9
Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma	9
B7-H3 Suppresses Antitumor Immunity via the CCL2–CCR2–M2 Macrophage Axis and Contributes to Ovarian Cancer Progression	9
Abstract P074: MB097: A therapeutic consortium of bacteria clinically-defined by precision microbiome profiling of immune checkpoint inhibitor patients with potent anti-tumor efficacy in vitro and in	9
PD-1/PD-L1–Associated Immunoarchitectural Patterns Stratify Pancreatic Cancer Patients into Prognostic/Predictive Subgroups	9
Resistance to Immune Checkpoint Blockade: IFNγ or MHC-I?	9
Immunologic Features in De Novo and Recurrent Glioblastoma Are Associated with Survival Outcomes	9
Artificial Intelligence Can Predict Personalized Immunotherapy Outcomes in Cancer	9
T-cell Therapies Targeting Multiple Cancer Antigens: The Power of Many	9
Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis	9
Immune-Guided Therapy of COVID-19	8
All Glioblastoma Are Not Equal: Distinct Spatial Immune Profiles BetweenDe Novoand Recurrent Tumors	8
Regional Variation in the Tumor Microenvironment, Immune Escape and Prognostic Factors in Breast Cancer in Sub-Saharan Africa	8
CD59-Regulated Ras Compartmentalization Orchestrates Antitumor T-cell Immunity	8
Intermittent MEK Inhibition with GITR Costimulation Rescues T-cell Function for Increased Efficacy with CTLA-4 Blockade in Solid Tumor Models	8
Abstract P028: Effects of histone deacetylase inhibition on major histocompatibility compatibility complex (MHC) class I expression, growth, and migration of cancer cells	8
Netrin-1 Promotes the Immunosuppressive Activity of MDSCs in Colorectal Cancer	8
Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine	8
Augmenting CAR T-cell Functions with LIGHT	8
Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR	8
Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade	8
Gefitinib Reverses PD-L1–Mediated Immunosuppression Induced by Long-term Glutamine Blockade in Bladder Cancer	8
A Sampling of Highlights from the Literature	8
KRT17 Promotes T-lymphocyte Infiltration Through the YTHDF2–CXCL10 Axis in Colorectal Cancer	8
Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors	8
Protection of Regulatory T Cells from Fragility and Inactivation in the Tumor Microenvironment	7
Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand–Expressing Solid Tumors	7
GPC2-targeted CAR T cells engineered with NFAT-inducible membrane-tethered IL-15/IL-21 exhibit enhanced activity against neuroblastoma	7
Molecular Signature of Tumor-Associated High Endothelial Venules That Can Predict Breast Cancer Survival	7
Linking Body Composition and Nutritional Status with CAR T-cell Efficacy	7
Abstract PR02: The co-expression of VISTA and TIGIT on cytotoxic T cells defines subpopulation with altered immunometabolism	7
First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell–Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic Melanoma	7
Abstract P008: Effect of route of Bacillus Calmette Guérin administration on the tumor immune microenvironment in a mouse model of non-muscle invasive bladder cancer	7
A Sampling of Highlights from the Literature	7
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer	7
Immunomodulatory Effects of RANK/RANKL Blockade in Patients with Cancer	7
Abstract P072: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) foster myeloid-derived suppressor cell-mediated tumor immune evasion in cholangiocarcinoma	7
PlexinB1 Inactivation Reprograms Immune Cells in the Tumor Microenvironment, Inhibiting Breast Cancer Growth and Metastatic Dissemination	7
Abstract P060: Identification of host-intrinsic resistance mechanisms to immune checkpoint inhibitors (ICI) in Diversity Outbred mice	7
Secretion of a VEGF-Blocking scFv Enhances CAR T-cell Potency	7
Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression	7
Abstract P063: Tumor cell-derived lactic acid inhibit anti-tumor immunity in the immune checkpoint blockade resistant tumor	7